TIDMSCLP

RNS Number : 3096T

Scancell Holdings Plc

11 October 2017

11 October 2017

Scancell Holdings Plc

("Scancell" or the "Company")

Results of AGM

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that all resolutions proposed at the Annual General Meeting were duly passed.

For Further Information:

 
 Dr John Chiplin, Executive                                +1 858 900 2646 
  Chairman                            Scancell Holdings     +44 (0) 20 3727 
  Dr Richard Goodfellow, CEO           Plc                  1000 
 
 Freddy Crossley (Corporate 
  Finance)                            Panmure Gordon &     +44 (0) 20 7886 
  Tom Salvesen (Corporate Broking)     Co                   2500 
 
                                                           +44 (0) 20 3727 
 Mo Noonan/Simon Conway               FTI Consulting        1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody(R) and Moditope(R) technology platforms.

Scancell's first ImmunoBody(R), SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell's ImmunoBody(R) vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer survival times than when either treatment was used alone.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope(R) platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGGIBDGBSBBGRB

(END) Dow Jones Newswires

October 11, 2017 04:44 ET (08:44 GMT)

Scancell (LSE:SCLP)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Scancell Charts.
Scancell (LSE:SCLP)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Scancell Charts.